title: Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.
abstract: The activating mutation JAK2 V617F plays a central role in the pathogenesis of polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Inhibition of JAK2 activity leads to growth inhibition and apoptosis in cells with mutated JAK2. However, the proapoptotic proteins involved in JAK2 inhibition-induced apoptosis remain unclear. In this study, we show that JAK2 inhibition-induced apoptosis correlated with up-regulation of the nonphosphorylated form of the BH3-only protein Bim in hematopoietic cell lines bearing JAK2 mutations. Knockdown of Bim dramatically inhibited apoptosis induced by JAK2 inhibition, which was reversed by the BH3 mimetic agent ABT-737. In addition, ABT-737 enhanced the apoptosis induced by JAK2 inhibition in JAK2 V617F(+) HEL and SET-2 cells. The combination of JAK inhibitor I and ABT-737 reduced the number of erythroid colonies derived from CD34(+) cells isolated from JAK2 V617F(+) polycythemia vera patients more efficiently than either drug alone. These data suggest that Bim is a key effector molecule in JAK2 inhibition-induced apoptosis and that targeting this apoptotic pathway could be a novel therapeutic strategy for patients with activating JAK2 mutations.
authors.affiliation: Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
authors.forename: Britta
authors.initials: B
authors.lastname: Will
authors.forename: Tanya
authors.initials: T
authors.lastname: Siddiqi
authors.forename: Meritxell Alberich
authors.initials: MA
authors.lastname: Jordà
authors.forename: Takeshi
authors.initials: T
authors.lastname: Shimamura
authors.forename: Katarina
authors.initials: K
authors.lastname: Luptakova
authors.forename: Philipp B
authors.initials: PB
authors.lastname: Staber
authors.forename: Daniel B
authors.initials: DB
authors.lastname: Costa
authors.forename: Ulrich
authors.initials: U
authors.lastname: Steidl
authors.forename: Daniel G
authors.initials: DG
authors.lastname: Tenen
authors.forename: Susumu
authors.initials: S
authors.lastname: Kobayashi
mesh_terms: D017209:Apoptosis / Q000187:drug effects* / Q000235:genetics; D051017:Apoptosis Regulatory Proteins / Q000235:genetics / Q000378:metabolism*; D000072224:Bcl-2-Like Protein 11; D040761:Biomimetic Materials / Q000494:pharmacology*; D001713:Biphenyl Compounds / Q000494:pharmacology*; D041905:Erythroid Cells / Q000378:metabolism*; D005260:Female; D006801:Humans; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000494:pharmacology*; D020014:K562 Cells; D008297:Male; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism*; D009154:Mutation; D009596:Nitrophenols / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology; D011087:Polycythemia Vera / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000378:metabolism*; D013449:Sulfonamides / Q000494:pharmacology*
chemical_list: C501332:ABT-737; D051017:Apoptosis Regulatory Proteins; C000606775:BCL2L11 protein, human; D000072224:Bcl-2-Like Protein 11; D001713:Biphenyl Compounds; D008565:Membrane Proteins; D009596:Nitrophenols; D010879:Piperazines; D011518:Proto-Oncogene Proteins; D013449:Sulfonamides; C507924:JAK2 protein, human; D053614:Janus Kinase 2